孕妇同时接种含流感与百日咳成分疫苗的安全性
该研究为基于澳大利亚新南威尔士州围产与免疫登记及住院数据的回顾性人群队列研究,纳入2021年1月1日至2022年3月12日末次月经的单胎妊娠孕妇及其婴儿。将孕20周及以上同时接种含流感与百日咳成分疫苗者与单独接种百日咳疫苗者按接种日期、接种时孕周和母亲年龄1:1匹配。共分析13918例单胎妊娠(6959对匹配),同时接种组早产264例(3.8%),对照组302例(4.4%);校正风险比0.83(95%CI 0.66-1.05)。小于胎龄儿校正比值比0.87(95%CI 0.74-1.04),低出生体重校正比值比0.94(95%CI 0.66-1.35),均无显著差异。结论认为同时接种未增加不良结局,可能有助于临床医生更自信地推荐孕期同时接种。
要点
- 孕妇同时接种含流感与百日咳成分疫苗与单独接种百日咳疫苗相比,早产率无显著差异:同时接种组3.8% vs 对照组4.4%,校正风险比0.83(95%CI 0.66-1.05)。
- 小于胎龄儿风险无显著差异:同时接种组8.8% vs 对照组9.9%,校正比值比0.87(95%CI 0.74-1.04)。
- 低出生体重风险无显著差异:同时接种组1.7% vs 对照组1.6%,校正比值比0.94(95%CI 0.66-1.35)。
- 死胎在总匹配队列中仅17例(0.1%),不足以进一步分析。
- 作者认为该结果可能帮助临床医生更自信地推荐孕期同时接种,并可能提供更多优化接种率的机会。
适用人群与场景
- 澳大利亚新南威尔士州单胎妊娠孕妇,末次月经估计在2021年1月1日至2022年3月12日之间,及其婴儿。
- 暴露组为孕20周及以上同时接种含流感与百日咳成分疫苗者;对照组为单独接种百日咳疫苗者。
研究设计与关键结果
- 研究类型:基于围产与免疫登记及住院数据链接的回顾性人群队列研究;共13918例单胎妊娠,其中6959例同时接种者与6959例单独接种百日咳疫苗者按接种日期、接种时孕周和母亲年龄1:1匹配(有放回匹配)。
- 母亲分娩时平均(标准差)年龄31.7(4.9)岁。
- 主要结局早产:同时接种组264例(3.8%) vs 对照组302例(4.4%),校正风险比0.83(95%CI 0.66-1.05),无显著差异。
- 主要结局小于胎龄儿(仅足月活产,6391对):同时接种组565例(8.8%) vs 对照组633例(9.9%),校正比值比0.87(95%CI 0.74-1.04),无显著差异。
- 主要结局低出生体重(仅足月活产):同时接种组107例(1.7%) vs 对照组105例(1.6%),校正比值比0.94(95%CI 0.66-1.35),无显著差异。
- 死胎:总匹配队列中17例(0.1%),不足以进一步分析。
- 次要结局(产前出血、产后出血、绒毛膜羊膜炎、子痫前期或子痫、胎膜早破、早产临产)在同时接种组与对照组之间无差异。
证据类型、等级与局限
- 证据类型:回顾性人群队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,该研究结果可能帮助临床医生更自信地推荐孕期同时接种含流感与百日咳成分疫苗,并可能提供更多优化接种率的机会。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Safety concerns are a barrier to vaccination during pregnancy. Although same-day administration of multiple vaccines may maximize uptake in pregnant women, few studies have focused on the safety of concomitant vaccination during pregnancy.
OBJECTIVE: To assess rates of pregnancy, birth, and neonatal outcomes following concomitant administration of influenza- and pertussis-containing vaccines in pregnant women compared with a matched control group.
DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study retrospectively analyzed linked data from perinatal and immunization registers and hospitalization data for women with singleton pregnancies in New South Wales, Australia, with estimated last menstrual period between January 1, 2021, and March 12, 2022, and their infants. Concomitant influenza and pertussis vaccination was compared with pertussis vaccination alone after 1:1 matching with replacement on vaccination date, gestation at vaccination, and maternal age. Data were analyzed between April and August 2025.
EXPOSURE: Women who received concomitant influenza- and pertussis-containing vaccine administration at 20 weeks' gestation or later were compared with those who received pertussis vaccination alone (control group).
MAIN OUTCOMES AND MEASURES: Primary outcomes were preterm birth, stillbirth, small for gestational age, and low birth weight. Secondary outcomes were antepartum hemorrhage, postpartum hemorrhage, chorioamnionitis, preeclampsia or eclampsia, prelabor rupture of membranes, and preterm labor. Pregnancy and birth outcomes were assessed using Cox models, and neonatal outcomes were assessed using logistic regression.
RESULTS: A total of 13 918 singleton pregnancies (6959 with concomitant vaccination matched to 6959 with pertussis vaccination alone) in women with a mean (SD) maternal age at delivery of 31.7 (4.9) years were analyzed. There were 264 (3.8%) preterm births in the concomitant vaccination group and 302 (4.4%) in the matched control group. Among term live births only (6391 pairs), 565 (8.8%) infants in the concomitant vaccination group and 633 (9.9%) in the control group were small for gestational age and 107 (1.7%) infants in the concomitant vaccination group and 105 (1.6%) in the control group had low birth weight. There were 17 (0.1%) stillbirths in the total matched cohort, precluding further analysis. No difference in the rate of preterm birth (adjusted hazard ratio, 0.83; 95% CI, 0.66-1.05) or the odds of small for gestational age (adjusted odds ratio [OR], 0.87; 95% CI, 0.74-1.04) or low birth weight (adjusted OR, 0.94; 95% CI, 0.66-1.35) between the matched groups was observed. There were no differences in rates between the concomitant vaccination and control groups for the secondary outcomes.
CONCLUSIONS AND RELEVANCE: In this cohort study, no association was found between concomitant influenza- and pertussis-containing vaccine administration during pregnancy and an increased rate of adverse pregnancy, birth, or neonatal outcomes compared with pertussis vaccination alone. These findings may help clinicians more confidently recommend vaccination concomitantly during pregnancy and potentially provide more opportunities to optimize uptake.
参考来源
- Sonneveld N, Reekie J, Deng L, et al. Coadministered Influenza- and Pertussis-Containing Vaccines in Pregnant Women. JAMA Netw Open. 2026. PMID: 41996114. doi:10.1001/jamanetworkopen.2026.7551
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。